These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18030018)

  • 41. [Impact of perioperative chemotherapy on prognosis of colorectal cancer: a report of 82 cases].
    Gong ZJ; Ren JQ; Kong G; Qing DJ; Liu H; Liang YQ
    Ai Zheng; 2007 Dec; 26(12):1350-3. PubMed ID: 18076799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A case of local recurrence of colon cancer responding to chemotherapy with low-dose oxaliplatin, 5-FU and l-LV].
    Seki H; Kurihara E; Iwata K; Saito J
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1291-3. PubMed ID: 17687216
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.
    Rosa DD; Awada A; Mano MS; Selleslags J; Lebrun F; Gil T; Piccart MJ; D'Hondt V
    Arch Gynecol Obstet; 2008 Nov; 278(5):457-62. PubMed ID: 18273626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A case with multiple liver metastases from rectal cancer responding completely to FOLFOX for a long duration without exacerbation of peripheral neuropathy].
    Nakae S; Mizojiri G; Fujikawa M; Ishida J; Yamamoto M; Harada N; Haji S; Toyoda M; Senzaki H
    Gan To Kagaku Ryoho; 2013 Feb; 40(2):255-8. PubMed ID: 23411967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature.
    Berretta M; Di Benedetto F; Bearz A; Simonelli C; Martellotta F; Del Ben C; Berretta S; Spina M; Tirelli U
    Cancer Invest; 2008 Jul; 26(6):610-4. PubMed ID: 18584352
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer.
    Aldulaymi B; Christensen IJ; Sölétormos G; Jess P; Nielsen SE; Brünner N; Nielsen HJ
    Anticancer Res; 2010 Jan; 30(1):233-7. PubMed ID: 20150641
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Administration of oxaliplatin to a pregnant woman with rectal cancer.
    Gensheimer M; Jones CA; Graves CR; Merchant NB; Lockhart AC
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):371-3. PubMed ID: 18357450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis.
    Watayo Y; Kuramochi H; Hayashi K; Nakajima G; Kamikozuru H; Yamamoto M
    Jpn J Clin Oncol; 2010 Apr; 40(4):360-4. PubMed ID: 20085906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [PSK decreased FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer].
    Shibata M; Shimura T; Nishina Y; Gonda K; Matsuo S; Abe H; Yajima Y; Nakamura I; Ohki S; Takenoshita S
    Gan To Kagaku Ryoho; 2011 May; 38(5):797-801. PubMed ID: 21566440
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use.
    Feliu J; Sereno M; Castro JD; Belda C; Casado E; González-Barón M
    Cancer Treat Rev; 2009 May; 35(3):246-54. PubMed ID: 19345021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Epiphora in a patient receiving FOLFOX therapy].
    Yatsuda C; Niimi M; Ono Y; Uto N; Iwagami E; Tanaka E; Yamato M
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1989-91. PubMed ID: 19011359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6.
    Laurent M; Des Guetz G; Bastuji-Garin S; Culine S; Caillet P; Aparicio T; Audureau E; Carvahlo-Verlinde M; Reinald N; Tournigand C; Landre T; LeThuaut A; Paillaud E; Canouï-Poitrine F
    Am J Clin Oncol; 2018 Jan; 41(1):73-80. PubMed ID: 26669742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial).
    Kotaka M; Yoshino T; Oba K; Shinozaki K; Touyama T; Manaka D; Matsui T; Ishigure K; Hasegawa J; Inoue K; Goto K; Sakamoto J; Saji S; Ohtsu A; Watanabe T
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):75-84. PubMed ID: 25983021
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma.
    Grem JL; Shoemaker DD; Petrelli NJ; Douglass HO
    Cancer Treat Rep; 1987 Nov; 71(11):1122. PubMed ID: 3499982
    [No Abstract]   [Full Text] [Related]  

  • 56. An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
    Brady J; Corrie P; Chau I; Digumarti R; Adams LM; Botbyl J; Laubscher KH; Midgley RS; Mallath M
    Invest New Drugs; 2013 Oct; 31(5):1228-35. PubMed ID: 23456563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.
    Popov I; Radosevic-Jelic L; Jezdic S; Milovic M; Borojevic N; Stojanovic S; Stankovic V; Josifovski T; Kezic I
    J BUON; 2008; 13(4):505-11. PubMed ID: 19145671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
    Cao W; Yang W; Lou G; Jiang J; Geng M; Xi W; Li H; Ma T; Jin Y
    Anticancer Drugs; 2009 Apr; 20(4):287-93. PubMed ID: 19177020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma.
    Chen JS; Chao Y; Yang TS; Chou WC; Chen LT; Lee KD; Lin YC
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):151-7. PubMed ID: 19455334
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
    Lévi F; Focan C; Karaboué A; de la Valette V; Focan-Henrard D; Baron B; Kreutz F; Giacchetti S
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1015-35. PubMed ID: 17692427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.